• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    InMode to Report First Quarter 2025 Financial Results and Hold Conference Call on April 28, 2025, Expects Q1 Revenue Between $77.2M-$77.5M, Reiterates FY 2025 Revenue Guidance Between $395M-$405M

    4/14/25 7:00:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $INMD alert in real time by email

    Conference call to be held on Monday, April 28, 2025, at 8:30 a.m. Eastern Time

    YOKNEAM, Israel, April 14, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the first quarter 2025 before the Nasdaq market opens on Monday, April 28, 2025.

    InMode Logo (PRNewsfoto/InMode)

    InMode is currently finalizing its financial results for the first quarter of 2025. While complete financial information and operating data are not yet available, set forth below are certain preliminary results of InMode's financial results for such period, subject to final adjustments and other developments that may arise between now and the time such financial results are finalized. Based on preliminary results, management expects:

    • Revenue for the first quarter of 2025 to be in the range of $77.2 million to $77.5 million
    • Non-GAAP1 gross margin to be in the range of 78% to 79%
    • Full year 2025 revenue to be in the range of $395 million to $405 million

    1Please refer to "Use of Non-GAAP Financial Measure" below for important information about non-GAAP financial measures. Non-GAAP results exclude share-based compensation.

    InMode will host a conference call to discuss the first quarter 2025 financial results on Monday, April 28, 2025, at 8:30 a.m. Eastern Daylight Time with presentations from management including Moshe Mizrahy, Chief Executive Officer, Yair Malca, Chief Financial Officer and Dr. Michael Kreindel, Chief Technology Officer.

    The Company encourages participants to pre-register for the conference call using the following link: https://dpregister.com/sreg/10198516/fede138cb8. Callers will receive a unique dial-in upon registration, which enables immediate access on the day of the call. Participants may pre-register at any time, including up to and after the call start time.

    For callers that opt out of pre-registration, please dial one of the following teleconferencing numbers. Please begin by placing your call 10 minutes before the conference call commences. If you are unable to connect using the toll-free number, please try the international dial-in number.

    U.S. Toll-Free: 1-833-316-0562

    Israel Toll-Free: 1-80-921-2373

    International: 1-412-317-5736                                                                                      

    Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=jNwaTGkH

    At:

    8:30 a.m. Eastern Time

    5:30 a.m. Pacific Time

    The conference call will also be webcast live from a link on InMode's website at https://inmodemd.com/investors/events-presentations/. A replay of the conference call will be available from April 28, 2025, at 12:00 p.m. Eastern Time to May 12, 2025, at 11:59 p.m. Eastern Time. To access the replay, please dial one of the following numbers:

    Replay U.S. TOLL-FREE: 1-877-344-7529

    Replay TOLL/INTERNATIONAL: 1-412-317-0088

    Replay Pin Number: 3039661

    A replay will also be available for 90 days on InMode's website at: https://inmodemd.com/investors/events-presentations/. 

    About InMode

    InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radio frequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode, please visit www.inmodemd.com.

    Forward-Looking Statements

    The information in this press release includes forward-looking statements within the meaning of the federal securities laws. These statements generally relate to future events or InMode's future financial or operating performance, including the 2025 revenue projection described above. Actual outcomes and results may differ materially from what is expressed or forecast in such forward-looking statements. In some cases, you can identify these statements because they contain words such as "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," "would" and similar expressions that concern our expectations, strategic plans or intentions. Forward-looking statements are based on management's current expectations and assumptions, and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Consequently, actual results could differ materially from those indicated in these forward-looking statements. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements included in InMode's Annual Report on Form 20-F filed with the Securities and Exchange Commission on February 04, 2025, and our future public filings. InMode undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which pertain only as of the date of this press release.

    Use of Non-GAAP Financial Measures

    In addition to InMode's operating results presented in accordance with GAAP, this release includes non-GAAP gross margin. Because this measure is used in InMode's internal analysis of financial and operating performance, management believes that it provides greater transparency to investors of management's view of InMode's economic performance. Management also believes the presentation of this measure, when analyzed in conjunction with InMode's GAAP operating results, allows investors to evaluate and compare the performance of InMode to that of its peers, although InMode's presentation of its non-GAAP measure may not be comparable to other similarly titled measures of other companies more effectively.

    Logo - https://mma.prnewswire.com/media/1064477/5263935/InMode_Logo.jpg

    Company Contact:

    Yair Malca

    Chief Financial Officer

    Email: [email protected]

    Investor Relations Contact:

    Miri Segal

    MS-IR LLC

    Email: [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/inmode-to-report-first-quarter-2025-financial-results-and-hold-conference-call-on-april-28--2025--expects-q1-revenue-between-77-2m-77-5m-reiterates-fy-2025-revenue-guidance-between-395m-405m-302426673.html

    SOURCE InMode Ltd.

    Get the next $INMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $INMD

    DatePrice TargetRatingAnalyst
    4/29/2025Buy → Neutral
    BTIG Research
    4/28/2025$22.00 → $16.00Outperform → Neutral
    Robert W. Baird
    10/17/2024$25.00Buy
    BTIG Research
    7/23/2024$21.00 → $19.00Buy → Hold
    Jefferies
    11/3/2023$52.00 → $24.00Buy → Neutral
    UBS
    10/13/2023$55.00 → $22.00Buy → Hold
    Canaccord Genuity
    3/29/2023$40.00Buy
    UBS
    2/17/2023Buy → Hold
    Needham
    More analyst ratings

    $INMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • InMode Response Letter to DOMA by Moshe Mizrahy, CEO, Dated May 28, 2025

      YOKNEAM, Israel, May 28, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today sent a letter to DOMA Perpetual Capital Management LLC ("DOMA") CEO and CIO Pedro Escudero in response to issues presented in his public letter dated May 9, 2025. The letter can be viewed here The full text of the letter follows: May 28, 2025 Mr. Pedro EscuderoCEO and CIODOMA, Perpetual Capital Management LLC Dear Mr. Escudero, This letter is in response to your letter dated May 9, 2025. First, I would like to thank you for voting for me to be re-elected to the Board of Directors. I really appreciate your vote of confidence and trust. I unde

      5/28/25 8:30:00 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • InMode Announces Health Canada Certification of the IgniteRF Platform with the New QuantumRF Technology

      YOKNEAM, Israel, May 20, 2025 /CNW/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, is pleased to announce Health Canada certification of IgniteRF, an advanced platform offering a comprehensive suite of minimally invasive radiofrequency solutions for the face and body.     IgniteRF is equipped with nine proprietary technologies, including the new QuantumRF, Morpheus8 Burst and Burst Deep, BodyTite Turbo, and FaceTite Turbo handpieces. This advanced complement of technologies leverages the heritage and efficacy of clinically proven bipolar radiofrequency to address consumer demand for minimal downtime procedures that deliver natural-looking results

      5/20/25 9:17:00 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • DOMA Perpetual Sends Letter Urging Board of Directors of InMode Ltd. to Resume Share Repurchase Program

      Believes the Board Should Immediately Resume and Accelerate Buybacks Asserts Board Should Remove Moshe Mizrahy as CEO of the Company MIAMI, May 9, 2025 /PRNewswire/ -- DOMA Perpetual Capital Management LLC, a significant stockholder of InMode Ltd. (NYSE: INMD) ("InMode"), today sent a letter to the Board of Directors of InMode (the "Board") urging the Board to continue its stock repurchase program and to replace its CEO.  The letter can be downloaded here The full text of the letter follows: May 9th, 2025 To the Board Members of InMode: For over a year, we have communicated p

      5/9/25 8:22:00 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care